Section one: Contracting authority
one.1) Name and addresses
Genomics England
One Canada Square
London
E14 5AB
supplier.engagement@genomicsengland.co.uk
Telephone
+44 2078825030
Country
United Kingdom
Region code
UKI - London
Internet address(es)
Main address
one.3) Communication
The procurement documents are available for unrestricted and full direct access, free of charge, at
https://genomicsengland.bravosolution.co.uk
Additional information can be obtained from the above-mentioned address
Tenders or requests to participate must be submitted electronically via
https://genomicsengland.bravosolution.co.uk
Tenders or requests to participate must be submitted to the above-mentioned address
one.4) Type of the contracting authority
Body governed by public law
one.5) Main activity
Health
Section two: Object
two.1) Scope of the procurement
two.1.1) Title
Process and Impact Evaluation
Reference number
GEL-SR-534-22
two.1.2) Main CPV code
- 73210000 - Research consultancy services
two.1.3) Type of contract
Services
two.1.4) Short description
Genomics England’s Generation Study aims to explore the benefits, challenges, and practicalities of offering whole genome sequencing to newborns, to accelerate diagnosis and access to treatment for rare genetic conditions. The programme funding was confirmed on 13 December 2022 with £105 million of funding to support it. Should it prove beneficial for participants and the wider health service, the study could pave the way for what would be the world’s first national newborn screening programme to incorporate whole genome sequencing.
The outcome for this project is for Genomics England to work in partnership with an organisation or group of organisations with the specific expertise to deliver the Generation Study evaluation. The Generation Study will:
1. evaluate the scientific and clinical utility and validity, operational feasibility, and impact on the NHS of using Whole Genome Sequencing to screen for a large number of childhood-onset rare genetic conditions and provide ongoing patient support
2. understand how, with consent, newborns’ genomic and health data could be used for research to enable new diagnostic discoveries and treatments to be developed
3. explore the potential risks, benefits, and broader implications of storing an individual’s genome over their lifetime (e.g., potential for preventative steps, personalised risk-based screening in later life etc.)
Please note that this tender seeks a partner to evaluate the first of these three aims only.
two.1.6) Information about lots
This contract is divided into lots: No
two.2) Description
two.2.2) Additional CPV code(s)
- 73000000 - Research and development services and related consultancy services
two.2.3) Place of performance
NUTS codes
- UKI - London
two.2.4) Description of the procurement
Two key components for which we require specific expertise in implementation science, behavioural science, health informatics and health economics are:
• Process Evaluation - will address research questions focusing specifically on whether the programme is acceptable and feasible. It will assess study delivery and processes to inform decision making for a possible future clinical service.
• Impact Evaluation - will address possible benefits and harms to:
o Stakeholders – including participants, Health Care professionals, and the public
o The System – including impact on existing newborn screening programmes and the impact on WGS for other patients as well as understanding comparative costs on the health care system.
o Experiences and Attitudes – including participants, the public and 3rd sector organisations.
Genomics England will act as sponsor for the Generation Study and associated evaluation work. Genomics England is ultimately accountable for the research of which this evaluation forms part. The successful Tenderer will be responsible for design and delivery of all research related activities pursuant to the bid, including but not limited to the delivery of documents for the HRA and any other relevant regulatory bodies (where necessary).
two.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
two.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Duration in months
18
This contract is subject to renewal
Yes
Description of renewals
An extension option of up to 12 months will be available for this contract
two.2.10) Information about variants
Variants will be accepted: No
two.2.11) Information about options
Options: No
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2.14) Additional information
Interested parties should register with Genomics England's e-tendering portal https://genomicsengland.bravosolution.co.uk and search for project_857 to access all relevant documentation.
Section three. Legal, economic, financial and technical information
three.1) Conditions for participation
three.1.2) Economic and financial standing
Selection criteria as stated in the procurement documents
three.1.3) Technical and professional ability
Selection criteria as stated in the procurement documents
three.2) Conditions related to the contract
three.2.3) Information about staff responsible for the performance of the contract
Obligation to indicate the names and professional qualifications of the staff assigned to performing the contract
Section four. Procedure
four.1) Description
four.1.1) Type of procedure
Open procedure
four.1.8) Information about the Government Procurement Agreement (GPA)
The procurement is covered by the Government Procurement Agreement: No
four.2) Administrative information
four.2.2) Time limit for receipt of tenders or requests to participate
Date
8 September 2023
Local time
12:00pm
four.2.4) Languages in which tenders or requests to participate may be submitted
English
four.2.6) Minimum time frame during which the tenderer must maintain the tender
Tender must be valid until: 1 November 2023
four.2.7) Conditions for opening of tenders
Date
8 September 2023
Local time
12:00pm
Section six. Complementary information
six.1) Information about recurrence
This is a recurrent procurement: No
six.2) Information about electronic workflows
Electronic ordering will be used
Electronic invoicing will be accepted
Electronic payment will be used
six.3) Additional information
Interested parties should register with Genomics England's e-tendering portal https://genomicsengland.bravosolution.co.uk and search for project_857 to access all relevant documentation.
six.4) Procedures for review
six.4.1) Review body
Public Procurement Review Service
London
Country
United Kingdom